Literature DB >> 11984067

Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy.

Takayuki Torigoe1, Hiroto Izumi, Tomoko Ise, Tadashi Murakami, Hidetaka Uramoto, Hiroshi Ishiguchi, Yoichiro Yoshida, Mizuho Tanabe, Minoru Nomoto, Kimitoshi Kohno.   

Abstract

Tumor cells in vivo often exist in a hypoxic microenvironment with a lower extracellular pH than that surrounding normal cells. Ability to upregulate proton extrusion may be important for tumor cell survival. Such microenvironmental factors may be involved in the development of resistant subpopulations of tumor cells. In solid tumors, both intracellular and extracellular pH differ between drug-sensitive and -resistant cells, and pH appears critical to the therapeutic effectiveness of anticancer agents. Four major types of pH regulators have been identified in tumor cells: the sodium-proton antiporter, the bicarbonate transporter, the proton-lactate symporter and proton pumps. Understanding mechanisms regulating tumor acidity opens up novel opportunities for cancer chemotherapy. In this minireview, we describe the structure and function of certain proton pumps overexpressed in many tumors--vacuolar H(+)-ATPases--and consider their potential as targets for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11984067     DOI: 10.1097/00001813-200203000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  9 in total

1.  Low pH enhances Sp1 DNA binding activity and interaction with TBP.

Authors:  Takayuki Torigoe; Hiroto Izumi; Yoichiro Yoshida; Hiroshi Ishiguchi; Takashi Okamoto; Hideaki Itoh; Kimitoshi Kohno
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

2.  Archazolid and apicularen: novel specific V-ATPase inhibitors.

Authors:  Markus Huss; Florenz Sasse; Brigitte Kunze; Rolf Jansen; Heinrich Steinmetz; Gudrun Ingenhorst; Axel Zeeck; Helmut Wieczorek
Journal:  BMC Biochem       Date:  2005-08-04       Impact factor: 4.059

3.  Uptake of clostridium botulinum C3 exoenzyme into intact HT22 and J774A.1 cells.

Authors:  Astrid Rohrbeck; Leonie von Elsner; Sandra Hagemann; Ingo Just
Journal:  Toxins (Basel)       Date:  2015-02-02       Impact factor: 4.546

Review 4.  The curious case of vacuolar ATPase: regulation of signaling pathways.

Authors:  Sahithi Pamarthy; Arpita Kulshrestha; Gajendra K Katara; Kenneth D Beaman
Journal:  Mol Cancer       Date:  2018-02-15       Impact factor: 27.401

5.  Computational modeling of methionine cycle-based metabolism and DNA methylation and the implications for anti-cancer drug response prediction.

Authors:  Mengying Zhang; Christian Saad; Lien Le; Kathrin Halfter; Bernhard Bauer; Ulrich R Mansmann; Jian Li
Journal:  Oncotarget       Date:  2018-02-21

6.  Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H⁺)-ATPase Inhibitors.

Authors:  Renukadevi Patil; Arpita Kulshrestha; Anjali Tikoo; Sara Fleetwood; Gajendra Katara; Bala Kolli; William Seibel; Alice Gilman-Sachs; Shivaputra A Patil; Kenneth D Beaman
Journal:  Molecules       Date:  2017-09-16       Impact factor: 4.411

7.  Intracellular pH regulation: characterization and functional investigation of H+ transporters in Stylophora pistillata.

Authors:  Laura Capasso; Philippe Ganot; Víctor Planas-Bielsa; Sylvie Tambutté; Didier Zoccola
Journal:  BMC Mol Cell Biol       Date:  2021-03-08

8.  An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS).

Authors:  Salvador Harguindey; Gorka Orive; Ramón Cacabelos; Enrique Meléndez Hevia; Ramón Díaz de Otazu; Jose Luis Arranz; Eduardo Anitua
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

Review 9.  Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs--an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research.

Authors:  Salvador Harguindey; Jose Luis Arranz; Julian David Polo Orozco; Cyril Rauch; Stefano Fais; Rosa Angela Cardone; Stephan J Reshkin
Journal:  J Transl Med       Date:  2013-11-06       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.